David is Executive Partner at Flagship Pioneering, Chairman of Axcella Health, Executive Chairman of Rubius Therapeutics, and a Board Member of Evelo Biosciences and International Flavors and Fragrances. Most recently, he served as Chief Executive Officer of Novartis Pharmaceuticals, a division of Novartis AG. Previously, David started and led Novartis’ Oncology program from 2001 – 2010. Under his leadership, as President and Chief Executive Officer, the company’s oncology business grew to the second largest in the world.
David has more than 25 years of extensive drug development, deal making, commercialization and leadership experience on a global scale. Over the course of his career he led the development and commercialization of over 30 new molecular entities, including major breakthroughs such as Glivec, Tasigna, Gilenya, Cosentyx and Entresto. He was recently named by FierceBiotech as one of the “25 Most Influential People in Biopharma”.
“Cellestia’s capability to control and modulate gene expression is a big step forward in developing new high potential breakthrough medicines for treatment of cancer and other indications.”
Early in his career, David was an associate in the Strategy Practice of the consulting firm Booz, Allen and Hamilton. David holds a BSc in Pharmacy with high honors from Rutgers University College of Pharmacy and an MBA in Finance and Marketing from the Columbia University Graduate School of Business.